Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213501 | 0.77 | POLB (0.38) | POLBKDM4ECYP3A4ALOX12TDP1 | |
| SCHEMBL1707825 | 0.73 | P2RX7 (0.32) | P2RX7AKR1B1LMNASMN1; SMN2 | |
| SCHEMBL2739293 | 0.72 | AKR1B1 (0.33) | P2RX7AKR1B1 | |
| SCHEMBL30168994 | 0.70 | P2RX7 (0.46) | P2RX7 | |
| SCHEMBL10857741 | 0.67 | POLB (0.80) | POLBKDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL10794105 | 0.67 | POLB (0.80) | POLBKDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL10794108 | 0.67 | POLB (0.80) | POLBKDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL15211128 | 0.67 | POLB (0.40) | POLBCYP3A4ALDH1A1HPGDMAPT | |
| SCHEMBL829076 | 0.66 | POLB (0.40) | POLB | |
| SCHEMBL15211580 | 0.66 | POLB (0.39) | POLBCYP3A4ALOX12TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | POLB 4829/4885P2RX7 671/4885AKR1B1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.